Stilla Technologies, a Villejuif, France and Beverly, MA-based multiplex digital PCR company, raised €31.3m in funding.
The round included:
- €11.3 million of convertible bonds; and
- €20m in loan financing.
In addition to new funding from existing investors Illumina Ventures, Kurma Partners, TusPark Capital Management, LBO France, BNP Paribas Developpement and Eurazeo, Stilla received investment from Casdin Capital and the European Investment Bank (EIB).
The company intends to use the funds to further expand its global commercial presence and develop its next generation digital PCR platform.
Most recently, the innovation leader launched the six-color naica® system, the industry’s highest multiplexing digital PCR system, already in high demand and being used by researchers and clinicians across a breadth of applications.
Led by Philippe Mourere, President and CEO, Stilla Technologies is a multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Its Crystal Digital PCR™ solution, the naica® system, is a digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians high multiplexing and detection capacity available on the market.
Stilla also has strategic distribution and business partnerships in China.